Yuxi Zerun Biotechnology Co., Ltd.

Primary purpose: To evaluate the long-term immune persistence of healthy women aged 9-30 years after bivalent HPV vaccination according to the 0, 2, and 6 month immunization schedule. Secondary purpose: To collect and analyze the occurrence of HPV-related diseases after vaccination and explore the long-term protective effect of bivalent HPV vaccine.

Primary objective: To evaluate the long-term protective efficacy of bivalent human papillomavirus vaccine (Pichia pastoris) in healthy women aged 18-30 years. Secondary objective: To evaluate the immune persistence of bivalent human papillomavirus vaccine (Pichia pastoris) in healthy women aged 18-30 years.

Primary objective: To evaluate the long-term immunity persistence of bivalent HPV vaccine in healthy women aged 9-26 years at the time of enrollment in the 311-HPV-1004 study (84 months, 108 months, and 132 months after the first dose). Secondary objective: To evaluate the neutralizing antibody levels at 0, 7, 12, 24, and 36 months in the 311-HPV-1004 study using a high-throughput pseudovirus assay (limited to subjects enrolled in this 311-HPV-1004-EXTEND study).